← Back to all trials
Not Yet Recruiting
NCT07530965
Omega-3-Fatty Acids in Children With Sickle Cell Disease
Conditions: Sickle Cell Disease (SCD)
Sex: All
Ages: 5 Years – 18 Years
Healthy volunteers: No
Phase: NA
Enrollment: 20
Sponsor: University of Alabama at Birmingham
Summary
The purpose of this feasibility study is to investigate the role of a dietary supplement in modulating the gut microbiota and improving pain outcomes in children with sickle cell disease (SCD).
Eligibility Criteria
Inclusion Criteria:
\- Children 5-18 years with SCD at steady state. Steady state will be defined as not requiring an acute care visit for pain in the last 28 days.
Exclusion Criteria:
* current use of antibiotics except prophylactic penicillin
* current use of pre-or probiotic supplements
* current use of PPI therapy
* pregnant or lactating females
* individuals with known allergy to Flaxseed
Source: ClinicalTrials.gov (NCT07530965). StuddyBuddy aggregates publicly available trial information.
